

June 23, 2006

Mr. Edward Greenspon  
Editor-in-Chief  
The Globe and Mail  
444 Front Street West  
Toronto, ON M5V 2S9

By e-mail ([egreenspon@globeandmail.ca](mailto:egreenspon@globeandmail.ca)) & regular mail

Dear Mr. Greenspon:

Re: A bitter but necessary pill to swallow, June 21, 2006.

Mr. Gold's statement that "the (pharmaceutical) industry has never met its promise of a 10-per cent investment in R&D" is inaccurate, misleading and simply not true.

The research-based pharmaceutical community had committed to a 10% R&D-to-sales-ratio as long as the government created an internationally competitive environment in which we could attract further investments in research and development (R&D) here at home.

Not only have we met our commitment but we've exceeded it. The Patented Medicines Prices Review Board (PMPRB) reported that Rx&D member companies achieved a research and development-to-sales ratio of over 10% for **10** consecutive years, reaching a high of 12.9%.

Furthermore, the PMPRB reports that Canadian prices of patented medicines were 8% below international median.

A declining environment has had an impact on our ability to invest in R&D in Canada.

We look forward to a regulatory environment that will allow our community to increase its investments in R&D.

Original signed by:

Russell Williams  
President